← All trials
NCT04927780
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 7, 2021
- Primary completion
- Feb 28, 2026
- Completion date
- Jul 31, 2029
- First posted
- Jun 16, 2021
- Last posted
- Oct 22, 2021
- Enrollment
- 378
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Erasmus University RotterdamLead sponsor
- Erasmus University RotterdamOverall official - principal investigator
- Erasmus University RotterdamReponsible party - principal investigator
- Dutch Cancer SocietyCollaborator
- Dutch Pancreatic Cancer GroupCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.